Jack Wallace
Stock Analyst at Guggenheim
(3.14)
# 1,091
Out of 5,172 analysts
18
Total ratings
57.89%
Success rate
273.86%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $184.07 | +35.27% | 4 | Oct 1, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $22.02 | -22.80% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $1.23 | +1,038.21% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $166.07 | +32.47% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $11.86 | +237.27% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $5.73 | +1,645.20% | 1 | Mar 15, 2023 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $184.07
Upside: +35.27%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $22.02
Upside: -22.80%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $1.23
Upside: +1,038.21%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $166.07
Upside: +32.47%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $11.86
Upside: +237.27%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $5.73
Upside: +1,645.20%